Literature DB >> 9199470

Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

E T Ryan1, J R Butterton, R N Smith, P A Carroll, T I Crean, S B Calderwood.   

Abstract

Clostridium difficile causes pseudomembranous colitis through the action of Rho-modifying proteins, toxins A and B. Antibodies directed against C. difficile toxin A prevent or limit C. difficile-induced colitis. We engineered plasmid pETR14, containing the hlyB and hlyD genes of the Escherichia coli hemolysin operon, to express a fusion protein containing 720 amino acid residues from the nontoxic, receptor-binding, carboxy terminus of C. difficile toxin A and the secretion signal of E. coli hemolysin A. We introduced pETR14 into Vibrio cholerae and found that the toxin A-HlyA fusion protein was secreted by a number of V. cholerae strains and recognized by both monoclonal and polyclonal anti-C. difficile toxin A antibodies. We introduced pETR14 into an attenuated V. cholerae strain, O395-NT, and inoculated rabbits orally with this construct. Colonization studies disclosed that the V. cholerae vector containing pETR14 was recoverable from rabbit ilea up to 5 days after oral inoculation. Vaccination produced significant systemic anti-C. difficile toxin A immunoglobulin G and anti-V. cholerae vibriocidal antibody responses. Vaccination also produced significant protection against toxin A in an ileal loop challenge assay, as assessed by determination of both fluid secretion and histological changes. These results suggest that the hemolysin system of E. coli can be used successfully in V. cholerae vector strains to effect secretion of large heterologous antigens and that a V. cholerae vector strain secreting a nontoxic, immunogenic portion of C. difficile toxin A fused to the secretion signal of E. coli HlyA induces protective systemic and mucosal immunity against this toxin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199470      PMCID: PMC175412          DOI: 10.1128/iai.65.7.2941-2949.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases.

Authors:  C von Eichel-Streiber; M Sauerborn
Journal:  Gene       Date:  1990-11-30       Impact factor: 3.688

2.  TolC, an Escherichia coli outer membrane protein required for hemolysin secretion.

Authors:  C Wandersman; P Delepelaire
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

Review 3.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

4.  Role of cholera toxin in enteric colonization by Vibrio cholerae O1 in rabbits.

Authors:  N F Pierce; J B Kaper; J J Mekalanos; W C Cray
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

5.  Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit.

Authors:  J Sanchez; A M Svennerholm; J Holmgren
Journal:  FEBS Lett       Date:  1988-12-05       Impact factor: 4.124

6.  Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains.

Authors:  J R Butterton; S A Boyko; S B Calderwood
Journal:  Vaccine       Date:  1993-10       Impact factor: 3.641

7.  Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis.

Authors:  J Hess; I Gentschev; D Miko; M Welzel; C Ladel; W Goebel; S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  Development of a live, oral, attenuated vaccine against El Tor cholera.

Authors:  D N Taylor; K P Killeen; D C Hack; J R Kenner; T S Coster; D T Beattie; J Ezzell; T Hyman; A Trofa; M H Sjogren
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

9.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Authors:  C P Kelly; C Pothoulakis; J Orellana; J T LaMont
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

10.  Synthesis in Vibrio cholerae and secretion of hepatitis B virus antigens fused to Escherichia coli heat-labile enterotoxin subunit B.

Authors:  F Schödel; H Will; S Johansson; J Sanchez; J Holmgren
Journal:  Gene       Date:  1991-03-15       Impact factor: 3.688

View more
  33 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

Review 4.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 5.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

6.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

7.  Induction of immune responses in mice after intragastric administration of Lactobacillus casei producing porcine parvovirus VP2 protein.

Authors:  Yigang Xu; Yijing Li
Journal:  Appl Environ Microbiol       Date:  2007-09-07       Impact factor: 4.792

8.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

9.  Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria.

Authors:  Corinne Grangette; Heide Müller-Alouf; Pascal Hols; Denise Goudercourt; Jean Delcour; Mireille Turneer; Annick Mercenier
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.

Authors:  Simon A Hirota; Vadim Iablokov; Sarah E Tulk; L Patrick Schenck; Helen Becker; Jimmie Nguyen; Samir Al Bashir; Tanis C Dingle; Austin Laing; Jianrui Liu; Yan Li; Jeff Bolstad; George L Mulvey; Glen D Armstrong; Wallace K MacNaughton; Daniel A Muruve; Justin A MacDonald; Paul L Beck
Journal:  Infect Immun       Date:  2012-10-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.